SI
HRTX icon

Sofinnova Investments’s Heron Therapeutics HRTX Stock Holding History

Sofinnova Investments’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,060
Closed -$63K – 62
2022
Q1 		$63K Sell
11,060
-2,922,291
-100% -$21.4M ﹤0.01% 61
2021
Q4 		$26.8M Buy
2,933,351
+632,172
+27% +$6.45M 1.56% 15
2021
Q3 		$24.6M Buy
2,301,179
+833,504
+57% +$10.1M 1.46% 14
2021
Q2 		$22.8M Buy
+1,467,675
New +$23.3M 1.31% 20
2020
Q2 		– Sell
-481,608
Closed -$5.65M – 84
2020
Q1 		$5.65M Buy
481,608
+431,108
+854% +$8.1M 0.52% 32
2019
Q4 		$1.19M Sell
50,500
-53,102
-51% -$1.17M 0.09% 57
2019
Q3 		$1.92M Sell
103,602
-513,583
-83% -$9.45M 0.17% 58
2019
Q2 		$11.5M Buy
617,185
+383,534
+164% +$7.66M 1.05% 23
2019
Q1 		$5.71M Sell
233,651
-126,062
-35% -$3.3M 0.55% 35
2018
Q4 		$9.33M Buy
359,713
+64,124
+22% +$1.76M 1.16% 21
2018
Q3 		$9.36M Buy
295,589
+37,004
+14% +$1.38M 0.83% 23
2018
Q2 		$10M Buy
258,585
+228,452
+758% +$7.27M 1.14% 22
2018
Q1 		$832K Buy
+30,133
New +$684K 0.14% 21

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Sofinnova Investments's HRTX Position: Q2 2022 in Review

Sofinnova Investments sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 11,060 shares — an estimated $63K sold.

Sofinnova Investments first reported a position in HRTX in Q1 2018 and held it in 13 quarters. The position peaked at $26.8M in Q4 2021. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

  • Sofinnova Investments reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Sofinnova Investments sold 11,060 Heron Therapeutics shares in Q2 2022, an estimated $63K.
  • Sofinnova Investments first reported a position in Heron Therapeutics in Q1 2018 and held it in 13 quarters.
  • Sofinnova Investments's Heron Therapeutics position peaked at $26.8M in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Sofinnova Investments's 13F filing for Q2 2022, filed 15 Aug 2022.